Reprogramming is the
next leap forward in cancer immunotherapy
ABOUT ASGARD THERAPEUTICS
Co-founder and CEO Cristiana Pires speaks about Asgard Therapeutics and explains how TrojanDC works.
An important hallmark of cancer is the ability to evade the immune system. Asgard Therapeutics has the ambitious goal to establish dendritic cell reprogramming as an entirely new approach to unleash the immune system against cancer.